| Literature DB >> 31908395 |
Christopher P Rice1, Krishnamurthy B Vaishnavi1, Celia Chao2, Daniel Jupiter3, August B Schaeffer1, Whitney R Jenson2, Lance W Griffin2, William J Mileski4.
Abstract
BACKGROUND: Recent management of acute cholecystitis favors same admission (SA) or emergent cholecystectomy based on overall shorter hospital stay and therefore cost savings. We adopted the practice of SA cholecystectomy for the treatment of acute cholecystitis at our tertiary care center and wanted to evaluate the economic benefit of this practice. We hypothesized that the existence of complications, particularly among patients with a higher degree of disease severity, during SA cholecystectomy could negate the cost savings. AIM: To compare complication rates and hospital costs between SA vs delayed cholecystectomy among patients admitted emergently for acute cholecystitis.Entities:
Keywords: Acute cholecystitis; Cholecystectomy; Complications; Delayed cholecystectomy; Tokyo guidelines
Mesh:
Year: 2019 PMID: 31908395 PMCID: PMC6938729 DOI: 10.3748/wjg.v25.i48.6916
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Demographics and patient characteristics
| Age at surgery | 44.7 ± 16.0 | 45.2 ± 15.7 | 0.812 |
| Female | 280 (64.8) | 49 (74.2) | 0.132 |
| Race/ethnicity | 0.447 | ||
| White | 183 (42.5) | 35 (53.0) | |
| Black | 57 (13.2) | 7 (10.6) | |
| Hispanic | 185 (42.9) | 23 (34.9) | |
| Other | 6 (1.4) | 1 (1.5) | |
| Body mass index | 32.2 ± 15.6 | 32.1 ± 6.4 | 0.93 |
| Comorbidities | |||
| Coronary artery disease | 13 (3.0) | 2 (3.0) | 1 |
| Myocardial infarction | 1 (0.2) | 0 (0.0) | 1 |
| Diabetes | 35 (8.1) | 4 (6.1) | 0.565 |
| Hypertension | 80 (18.5) | 18 (27.3) | 0.096 |
| Chronic obstructive pulmonary disease | 3 (0.7) | 1 (1.5) | 0.435 |
| Alcohol use | 134 (42.8) | 27 (46.6) | 0.598 |
| Smoking status | 100 (26.1) | 20 (31.3) | 0.39 |
| Open cholecystectomy | 8 (1.7) | 3 (4.4) | 0.142 |
| Convert-to-open cholecystectomy | 7 (1.4) | 2 (2.9) | 0.305 |
Stratification by disease severity using 2013/18 Tokyo guidelines, n (%)
| Acute cholecystitis severity | |||
| Tokyo Grade 1 | 299 (61.5) | 36 (52.9) | 0.271 |
| Tokyo Grade 2 | 174 (35.8) | 31 (45.6) | |
| Tokyo Grade 3 | 13 (2.7) | 1 (1.5) | |
| Tokyo criteria | mean ± SD | mean ± SD | |
| White blood cell count | 11.8 ± 4.5 | 11.4 ± 3.8 | 0.605 |
| Duration of complaints | 1.9 ± 7.3 | 1.4 ± 3.2 | 0.578 |
| Palpable tender mass in RUQ | 8 (1.6) | 1 (1.5) | 1 |
| Marked local inflammation | 66 (13.6) | 13 (19.1) | 0.221 |
| Creatinine | 0.9 ± 0.8 | 0.7 ± 0.2 | 0.104 |
| International normalized ratio | 1.1 ± 0.2 | 1.4 ± 0.7 | 0.534 |
| Platelet count | 271.9 ± 73.8 | 282.6 ± 92.0 | 0.633 |
| Cardiovascular dysfunction | 2 (0.41) | 0 (0.0) | 1 |
| Neurological dysfunction | 0 (0.0) | 0 (0.0) | 1 |
| Respiratory dysfunction | 0 (0.0) | 0 (0.0) | 1 |
| Other vitals and laboratory values | |||
| Temperature (˚C) | 36.7 ± 0.4 | 36.6 ± 0.4 | 0.068 |
| Total bilirubin | 1.0 ± 1.4 | 1.1 ± 1.7 | 0.852 |
| Direct bilirubin | 0.1 ± 0.6 | 0.5 ± 1.5 | 0.474 |
| Aspartate aminotransferase | 89.5 ± 181.6 | 64 ± 100.6 | 0.32 |
| Alanine aminotransferase | 94.9 ± 181.8 | 70.0 ± 96.4 | 0.32 |
| Alkaline phosphatase | 102.3 ± 48.6 | 111.4 ± 69.6 | 0.591 |
| Amylase | 87.6 ± 235.5 | 54 ± 5.3 | 0.112 |
| Lipase | 207.6 ± 704.7 | 477.2 ± 1474.5 | 0.478 |
RUQ: Right upper quadrant.
Complication rates and types, n (%)
| Total patients with at least 1 complication | 90 (18.5) | 3 (4.4) | 0.004 |
| Tokyo Grade 1 | 37 (12.4) | 3 (8.3) | 0.480 |
| Tokyo Grade 2 | 46 (26.4) | 0 (0.0) | < 0.001 |
| Tokyo Grade 3 | 7 (53.8) | 0 (0.0) | 1 |
| Subtotal cholecystectomy | 37 (7.6) | 0 (0.0) | 0.016 |
| Death | 3 (0.6) | 0 (0.0) | 1 |
| Hepatobiliary | |||
| Common bile duct injury | 0 (0.0) | 0 (0.0) | – |
| Bile leak | 9 (1.9) | 0 (0.0) | 0.610 |
| Retained stone | 12 (2.5) | 0 (0.0) | 0.377 |
| Cholangitis | 2 (0.4) | 0 (0.0) | 1 |
| Biliary stenosis | 3 (0.6) | 0 (0.0) | 1 |
| Infection | |||
| Wound infection | 10 (2.1) | 0 (0.0) | 0.620 |
| Abscess | 2 (0.4) | 0 (0.0) | 1 |
| Sepsis | 1 (0.2) | 1 (1.5) | 0.231 |
| 3 (0.6) | 0 (0.0) | 1 | |
| Intravenous catheter infection | 1 (0.2) | 0 (0.0) | 1 |
| Cardiovascular | |||
| Hemorrhage | 4 (0.8) | 1 (1.5) | 0.482 |
| Hemorrhagic shock | 1 (0.2) | 0 (0.0) | 1 |
| Cardiogenic shock | 1 (0.2) | 0 (0.0) | 1 |
| Congestive heart failure exacerbation | 3 (0.6) | 0 (0.0) | 1 |
| Chest pain | 1 (0.2) | 0 (0.0) | 1 |
| Respiratory | |||
| Pneumonia | 4 (0.8) | 1 (1.5) | 0.482 |
| Respiratory failure | 2 (0.4) | 0 (0.0) | 1 |
| Pulmonary embolism | 1 (0.2) | 0 (0.0) | 1 |
| Pulmonary edema | 1 (0.2) | 0 (0.0) | 1 |
| Pleural effusion | 1 (0.2) | 0 (0.0) | 1 |
| Gastrointestinal | |||
| Pancreatitis | 6 (1.2) | 0 (0.0) | 1 |
| Gastroenteritis | 1 (0.2) | 0 (0.0) | 1 |
| Small bowel injury | 1 (0.2) | 0 (0.0) | 1 |
| Ileus | 2 (0.4) | 0 (0.0) | 1 |
| Hernia | |||
| Ventral hernia | 1 (0.2) | 0 (0.0) | 1 |
| Incisional hernia | 2 (0.4) | 1 (1.5) | 0.325 |
| Other | |||
| Seizure | 1 (0.2) | 0 (0.0) | 1 |
| Wound dehiscence | 2 (0.4) | 0 (0.0) | 1 |
| Reactive hydrocele | 1 (0.2) | 0 (0.0) | 1 |
Level of significance was
P < 0.05.
Hospital length of stay, postoperative readmissions, and charges
| Time to surgical admission (d) | 48.3 ± 76.3 | ||
| Surgical admission length of stay (d) | 3.4 ± 5.3 | 0.4 ± 1.0 | < 0.001 |
| Preoperative (d) | 2.2 ± 14.2 | 0.0 ± 0.2 | < 0.001 |
| Postoperative (d) | 1.2 ± 14.8 | 0.4 ± 0.9 | 0.204 |
| Readmissions after cholecystectomy | |||
| Patients with at least 1 readmission | 96 (22.2) | 14 (21.2) | 0.854 |
| Mean number of readmissions Among those readmitted | 1.8 ± 1.5 | 1.4 ± 0.6 | 0.074 |
| Total length of stay | 3.8 ± 5.5 | 1.6 ± 2.0 | < 0.001 |
| Total hospital charges (× $1000) | 44.5 ± 59.0 | 35.3 ± 16.7 | 0.019 |
Total length of stay includes index admission, elective operative admission for delayed cases, and all postoperative complication-related readmissions.
Hospital charges for April 2013-August 2018 only. Level of significance was
P < 0.05.
Logistic regression analysis
| Occurrence of any complication - all patients | ||||
| Same admission cholecystectomy | 0.7 | 0.1-7.7 | 0.759 | |
| Grade 2 | 2.1 | 1.2-3.7 | 0.007 | |
| Grade 3 | 2.0 | 0.4-10.2 | 0.404 | |
| Male | 1.4 | 0.8-2.5 | 0.262 | |
| Diabetes | 1.2 | 0.5-3.1 | 0.722 | |
| Hypertension | 1.1 | 0.5-2.4 | 0.773 | |
| Open cholecystectomy | 1.1 | 0.2-5.4 | 0.863 | |
| Insurance status | 0.6 | 0.3-1.2 | 0.180 | |
| Age | 1.0 | 1.0-1.0 | 0.919 | |
| Creatinine | 0.9 | 0.7-1.4 | 0.780 | |
| Occurrence of any complication - Grade 1 patients | ||||
| Same admission cholecystectomy | 0.2 | 0.0-1.3 | 0.094 | |
| Diabetes | 2.5 | 0.7-9.0 | 0.157 | |
| Insurance status | 0.3 | 0.1-1.0 | 0.052 | |
| Body mass index | 1.1 | 1.0-1.1 | 0.048 | |
| Occurrence of any complication - Grade 2 patients | ||||
| Male | 1.9 | 0.7-5.4 | 0.238 | |
| Smoking status | 2.1 | 0.8-5.7 | 0.156 | |
| Open cholecystectomy | 2.1 | 0.1-31.8 | 0.598 | |
| Age | 1.0 | 1.0-1.0 | 0.975 | |
| Body mass index | 1.0 | 1.0-1.1 | 0.277 | |
| Postoperative length of stay | 1.4 | 1.0-2.1 | 0.056 | |
| Aspartate aminotransferase | 1.0 | 1.0-1.0 | 0.848 | |
| Alanine aminotransferase | 1.0 | 1.0-1.0 | 0.481 | |
| Lipase | 1.0 | 1.0-1.0 | 0.482 | |
| Creatinine | 2.8 | 0.3-30.7 | 0.402 | |
| Occurrence of any complication - Grade 2 or 3 patients | ||||
| Male | 2.3 | 1.0-5.1 | 0.047 | |
| Open cholecystectomy | 1.3 | 0.2-9.5 | 0.767 | |
| Age | 1.0 | 1.0-1.0 | 0.326 | |
| Body mass index | 1.0 | 1.0-1.0 | 0.565 | |
| Preoperative length of stay | 0.8 | 0.6-1.0 | 0.061 | |
| Creatinine | 1.0 | 0.7-1.4 | 0.919 | |
Level of significance was
P < 0.05. OR: Odds ratio; CI: Confidence interval.
Relative risk, attributable risk, and number needed to harm analysis
| All, SA | ||
| Relative risk | 4.2x | 1.4 to 12.9 |
| Attributable risk | 14.1% | 4.6 to 23.6 |
| Number needed to harm | 8 | 5.0 to 12.3 |
| Grade 1, SA | ||
| Relative risk | 1.7x | 0.5 to 5.1 |
| Attributable risk | 4.9% | -5.7 to 15.5 |
| Number needed to harm | 21 | -7.2 to 24.4 |
| Grade 2, SA | ||
| Relative risk | – | – |
| Attributable risk | 26.4% | 13.2 to 39.7 |
| Number needed to harm | 4 | 3.0 to 5.0 |
| Grade 2 or 3 | ||
| Relative risk | – | – |
| Attributable risk | 28.3% | 12.3 to 44.4 |
| Number needed to harm | 4 | 2.9 to 4.6 |
Relative risk analysis could not be performed in Grades 2 or 3 due to zero complications in the delayed group.
Due to a small sample size of the rarer Grade 3 disease, combined analysis of Grades 2 and 3 was performed to represent all moderate and severe cases.
Statistically significant. CI: Confidence Interval; SA: Same admission.